These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32541024)

  • 1. Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade.
    Wang Y; Nanda V; Direnzo D; Ye J; Xiao S; Kojima Y; Howe KL; Jarr KU; Flores AM; Tsantilas P; Tsao N; Rao A; Newman AAC; Eberhard AV; Priest JR; Ruusalepp A; Pasterkamp G; Maegdefessel L; Miller CL; Lind L; Koplev S; Björkegren JLM; Owens GK; Ingelsson E; Weissman IL; Leeper NJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15818-15826. PubMed ID: 32541024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EphA2 Expression Regulates Inflammation and Fibroproliferative Remodeling in Atherosclerosis.
    Finney AC; Funk SD; Green JM; Yurdagul A; Rana MA; Pistorius R; Henry M; Yurochko A; Pattillo CB; Traylor JG; Chen J; Woolard MD; Kevil CG; Orr AW
    Circulation; 2017 Aug; 136(6):566-582. PubMed ID: 28487392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of efferocytosis in atherosclerosis.
    Shu LX; Cao LL; Guo X; Wang ZB; Wang SZ
    J Mol Med (Berl); 2024 Jul; 102(7):831-840. PubMed ID: 38727748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis.
    Jarr KU; Kojima Y; Weissman IL; Leeper NJ
    Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):e145-e154. PubMed ID: 35387480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efferocytosis in atherosclerotic lesions: Malfunctioning regulatory pathways and control mechanisms.
    Tajbakhsh A; Rezaee M; Kovanen PT; Sahebkar A
    Pharmacol Ther; 2018 Aug; 188():12-25. PubMed ID: 29444453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sonodynamic Therapy Promotes Efferocytosis via CD47 Down-Regulation in Advanced Atherosclerotic Plaque.
    Cao Y; Yao J; Gao W; Cao Z; Diabakte K; Wang L; Sun X; Tian Y
    Int Heart J; 2022 Jan; 63(1):131-140. PubMed ID: 35034916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin beta3 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells.
    Misra A; Feng Z; Chandran RR; Kabir I; Rotllan N; Aryal B; Sheikh AQ; Ding L; Qin L; Fernández-Hernando C; Tellides G; Greif DM
    Nat Commun; 2018 May; 9(1):2073. PubMed ID: 29802249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2
    Wang W; Liu W; Fidler T; Wang Y; Tang Y; Woods B; Welch C; Cai B; Silvestre-Roig C; Ai D; Yang YG; Hidalgo A; Soehnlein O; Tabas I; Levine RL; Tall AR; Wang N
    Circ Res; 2018 Nov; 123(11):e35-e47. PubMed ID: 30571460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SM22α (Smooth Muscle Protein 22-α) Promoter-Driven IGF1R (Insulin-Like Growth Factor 1 Receptor) Deficiency Promotes Atherosclerosis.
    Sukhanov S; Higashi Y; Shai SY; Snarski P; Danchuk S; D'Ambra V; Tabony M; Woods TC; Hou X; Li Z; Ozoe A; Chandrasekar B; Takahashi SI; Delafontaine P
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2306-2317. PubMed ID: 30354209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DKK3 (Dickkopf 3) Alters Atherosclerotic Plaque Phenotype Involving Vascular Progenitor and Fibroblast Differentiation Into Smooth Muscle Cells.
    Karamariti E; Zhai C; Yu B; Qiao L; Wang Z; Potter CMF; Wong MM; Simpson RML; Zhang Z; Wang X; Del Barco Barrantes I; Niehrs C; Kong D; Zhao Q; Zhang Y; Hu Y; Zhang C; Xu Q
    Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):425-437. PubMed ID: 29284609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-efferocytic nanotherapies reduce vascular inflammation without inducing anemia in a large animal model of atherosclerosis.
    Bamezai S; Zhang Y; Kumari M; Lotfi M; Alsaigh T; Luo L; Kumar GS; Wang F; Ye J; Puri M; Manchanda R; Paluri S; Adkar SS; Kojima Y; Ingelsson A; Bell CF; Lopez NG; Fu C; Choi RB; Miller Z; Barrios L; Walsh S; Ahmad F; Maegdefessel L; Smith BR; Leeper NJ
    Nat Commun; 2024 Sep; 15(1):8034. PubMed ID: 39271657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis.
    Kiss MG; Papac-Miličević N; Porsch F; Tsiantoulas D; Hendrikx T; Takaoka M; Dinh HQ; Narzt MS; Göderle L; Ozsvár-Kozma M; Schuster M; Fortelny N; Hladik A; Knapp S; Gruber F; Pickering MC; Bock C; Swirski FK; Ley K; Zernecke A; Cochain C; Kemper C; Mallat Z; Binder CJ
    Immunity; 2023 Aug; 56(8):1809-1824.e10. PubMed ID: 37499656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large Extracellular Vesicle-Associated Rap1 Accumulates in Atherosclerotic Plaques, Correlates With Vascular Risks and Is Involved in Atherosclerosis.
    Perdomo L; Vidal-Gómez X; Soleti R; Vergori L; Duluc L; Chwastyniak M; Bisserier M; Le Lay S; Villard A; Simard G; Meilhac O; Lezoualc'h F; Khantalin I; Veerapen R; Dubois S; Boursier J; Henni S; Gagnadoux F; Pinet F; Andriantsitohaina R; Martínez MC;
    Circ Res; 2020 Aug; 127(6):747-760. PubMed ID: 32539601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allograft inflammatory factor-1 supports macrophage survival and efferocytosis and limits necrosis in atherosclerotic plaques.
    Egaña-Gorroño L; Chinnasamy P; Casimiro I; Almonte VM; Parikh D; Oliveira-Paula GH; Jayakumar S; Law C; Riascos-Bernal DF; Sibinga NES
    Atherosclerosis; 2019 Oct; 289():184-194. PubMed ID: 31439353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation.
    Ye ZM; Yang S; Xia YP; Hu RT; Chen S; Li BW; Chen SL; Luo XY; Mao L; Li Y; Jin H; Qin C; Hu B
    Cell Death Dis; 2019 Feb; 10(2):138. PubMed ID: 30755588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.
    Kojima Y; Volkmer JP; McKenna K; Civelek M; Lusis AJ; Miller CL; Direnzo D; Nanda V; Ye J; Connolly AJ; Schadt EE; Quertermous T; Betancur P; Maegdefessel L; Matic LP; Hedin U; Weissman IL; Leeper NJ
    Nature; 2016 Aug; 536(7614):86-90. PubMed ID: 27437576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis.
    Shankman LS; Gomez D; Cherepanova OA; Salmon M; Alencar GF; Haskins RM; Swiatlowska P; Newman AA; Greene ES; Straub AC; Isakson B; Randolph GJ; Owens GK
    Nat Med; 2015 Jun; 21(6):628-37. PubMed ID: 25985364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The age of bone marrow dictates the clonality of smooth muscle-derived cells in atherosclerotic plaques.
    Kabir I; Zhang X; Dave JM; Chakraborty R; Qu R; Chandran RR; Ntokou A; Gallardo-Vara E; Aryal B; Rotllan N; Garcia-Milian R; Hwa J; Kluger Y; Martin KA; Fernández-Hernando C; Greif DM
    Nat Aging; 2023 Jan; 3(1):64-81. PubMed ID: 36743663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TUG1 knockdown ameliorates atherosclerosis via up-regulating the expression of miR-133a target gene FGF1.
    Zhang L; Cheng H; Yue Y; Li S; Zhang D; He R
    Cardiovasc Pathol; 2018; 33():6-15. PubMed ID: 29268138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impaired Mechanism and Facilitated Therapies of Efferocytosis in Atherosclerosis.
    Wang Z; Su J; Gong F; Xue L; Su Z
    J Cardiovasc Pharmacol; 2022 Sep; 80(3):407-416. PubMed ID: 35853202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.